Stockscreener 앱 받기
4.70
0.84%
-0.04
시간 외 거래:
4.75
0.05
+1.06%
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
How many analysts rate Vanda Pharmaceuticals Inc. as a “Buy”Overwhelming profit margins - jammulinksnews.com
Should I hold or sell Vanda Pharmaceuticals Inc. stock in 2025Free Trading Psychology Coaching - jammulinksnews.com
How does Vanda Pharmaceuticals Inc. generate profit in a changing economyBuild a diversified portfolio for stability - jammulinksnews.com
What institutional investors are buying Vanda Pharmaceuticals Inc. stockAchieve consistent profits with disciplined trading - jammulinksnews.com
Is Vanda Pharmaceuticals Inc. a growth stock or a value stockExceptional trading performance - jammulinksnews.com
Is Vanda Pharmaceuticals Inc. a good long term investmentRapid wealth accumulation - PrintWeekIndia
When is the best time to buy Vanda Pharmaceuticals Inc. stockPowerful profit generation - jammulinksnews.com
Vanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025 - Barchart.com
Vanda Pharmaceuticals Inc. Stock Analysis and ForecastSkyrocketing investment returns - jammulinksnews.com
What analysts say about Vanda Pharmaceuticals Inc. stockAccelerated capital growth - Autocar Professional
What drives Vanda Pharmaceuticals Inc. stock priceMassive profits - jammulinksnews.com
Why Vanda Pharmaceuticals Inc. stock attracts strong analyst attentionSmart Growth Low Risk Picks - beatles.ru
Vanda Pharmaceuticals’ Study on Trichostatin A: A Potential Game-Changer in Hematologic Malignancies - TipRanks
US FDA Will Not Pull Teva And MSN Hetlioz ANDAs, Rejects Vanda Citizen Petitions - insights.citeline.com
Vanda Pharmaceuticals Inc.(NasdaqGM: VNDA) added to Russell 2000 Defensive Index - MarketScreener
Insider Sell: Stephen Mitchell Sells 7,000 Shares of Vanda Pharm - GuruFocus
DC Circ. Urged To Reject Approval For Braille-Free Drug Label - Law360
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S - StreetInsider
Vanda Pharmaceuticals Inc. Announces First Patient Dosed in A Trial Evaluating VCA-894A in Charcot-Marie-Tooth Disease Type 2S - MarketScreener
Vanda Pharmaceuticals Announces First Patient Dosed In A Trial Evaluating VCA-894A In Charcot-Marie-Tooth Disease Type 2S - MarketScreener
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial E - GuruFocus
Vanda Pharmaceuticals (VNDA) Initiates First Human Trial for Ant - GuruFocus
Vanda's Breakthrough: First-Ever Personalized Treatment Trial Launches for Ultra-Rare CMT2S Disease - Stock Titan
Vanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S | VNDA Stock News - GuruFocus
Director Honore Tage was granted 59,225 shares, increasing direct ownership by 92% to 123,469 units (SEC Form 4) - Quantisnow
Vanda Approves Key Proposals at Annual Meeting - TipRanks
SEC Form S-8 filed by Vanda Pharmaceuticals Inc. - Quantisnow
CLASS ACTION UPDATE for SPB, VNDA and ARA: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders - ACCESS Newswire
1.32%
1.06%
자본화:
|
볼륨(24시간):